INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5438 participants.

Also called NCT03871517

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,438 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03871517
Other papers using this trial's data
  • Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial The Lancet. Neurology, 2023-06 DOI, PubMed 37121237

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03871517. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2022-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
Condition
Indobufen
Condition
Aspirin
Intervention (Drug)
Indobufen
Intervention (Drug)
Aspirin
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct03871517
Content hash
ef6a2ef082ade717883af57326e1a727481e04dae36bb35281bb883b75881ce8